GeneInsight was developed by Partners HealthCare and a team of geneticists, laboratory operations personnel, physicians and IT professionals. The software collects genetic data and produces an individualized analysis of a patient which can help inform treatments or indicate how a patient may respond to certain medications.
“There’s a global opportunity here,” Calum MacRae, MD, PhD, chief of cardiovascular medicine at Partners-owned Brigham and Women’s Hospital, told The Boston Globe. Dr. MacRae uses GeneInsight with his patients. “This is the type of tool that changes the game. Partners is beginning to take a more outward approach to novel technologies. That will change the revenue streams that we’re so dependent on.”
Partners recently signed a deal to sell GeneInsight to Sunquest Information Systems, who plans to market the software to hospitals and labs just beginning to conduct genetic tests, according to the report.
“We expect Sunquest to build a substantial business that will benefit hundreds of thousands, if not millions, of patients,” Christopher M. Coburn, vice president of innovation at Partners, told The Boston Globe.
More articles on health IT:
5 things to know about the GE Health Cloud
GOP Doctors Caucus pens letter to Paul Ryan asking for MU delay, hardship exceptions
Lahey to pay $850k HIPAA settlement for 2011 data breach
